The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are permitted when drugs are listed on the FDA’s list of drug shortages. These shortages can occur for many reasons, including manufacturing and quality disruptions, discontinuation, and delays. The FDA has permitted compounded GLP-1 products, which are not to be confused with generics, to be produced to meet the heavy market demand while branded GLP-1 drugs from Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY) remain in short supply. Here are two alternative stocks riding the GLP-1 weight loss trend.
